Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
-
Eagle-eyed Spaun snatches Texas Open victory
-
Brown, Tatum propel Celtics in win over Raptors
-
Paul battles past Burruchaga to win ATP Houston title
-
Major sponsors drop Kanye West London gigs as PM voices concern
-
Inter close in on Serie A title by thumping Roma
-
Trump makes foul-mouthed threat to Iran after US airman rescued
-
Monaco sink Marseille for seventh Ligue 1 win in a row
-
Inter thump Roma to extend Serie A lead to nine points
-
Lebanon's Christians mark Easter in solidarity with war-hit south
-
Leeds beat West Ham in shoot-out to reach FA Cup semis for first time in 39 years
-
Pegula romps to WTA Charleston Open victory
-
David six-hitting spree powers Bengaluru to IPL win
-
Union draw leaves St Pauli stranded in Bundesliga drop zone
-
UK police arrest protesters near base used by US
-
Trump issues foul-mouthed threat to Iran after US airman rescued
-
Alcaraz plans to play full clay-court season, get 'socks dirty'
-
'Super Mario Galaxy' blasts off in N. America box office debut
-
Artemis astronauts begin fifth day on historic Moon mission
-
Bielle-Biarrey sparkles as Bordeaux-Begles cruise in Champions Cup
-
Trump draws criticism with fiery Easter message on Iran
-
OPEC+ hikes oil production quotas, issues warning
-
British PM slams London event for booking Kanye West, sponsor quits
-
Pogacar wins joint-record third Tour of Flanders
-
Trump threatens 'hell' for Iran over Strait of Hormuz
-
Shami, Pant help Lucknow beat Hyderabad in nervy IPL clash
-
What we know about the race to rescue downed US airman in Iran
-
US commandos went deep into Iran to rescue downed airman: media
-
Liberated McIlroy eyes more Masters magic after career Slam
-
Van Dijk apologises for Liverpool thumping by Man City
-
British PM slams London festival for booking Kanye West
-
'Choose peace': Pope marks first Easter under cloud of Mideast war
-
British royals attend Easter service without Andrew
-
US media says commandos probed deep into Iran to rescue downed airman
-
Revellers parade giant penises to dash stigma in Japan's fertility festival
-
Artemis astronauts glimpse Moon's 'Grand Canyon' ahead of historic lunar flyby
-
Middle East war hits Britain's fish and chip shops
-
Artemis astronauts to study the Moon's surface using mainly their eyes
-
Second US airman downed over Iran 'SAFE and SOUND': Trump
-
Indonesia lays to rest peacekeepers killed in Lebanon
-
Pharmaceutical logistics in demand as war rattles supply chains
-
Messi marks new stadium with goal but Miami held by Austin
-
Afghan mother seeks justice after Pakistani bombing kills hundreds
-
UK royal family's dilemma over Andrew's daughters
-
Pope marks first Easter under cloud of Mideast war
-
AI at war: Five things to know about Project Maven
-
In the online 'maxxing' era, what's the deal with fiber and protein?
-
At Met Opera, life after a school shooting takes center stage
-
Taiwan opposition leader to make 'peace' visit to China, first in 10 years
-
McIlroy seeks rare Masters repeat in wide-open Augusta fight
-
Israel says will strike Lebanon-Syria border crossing
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
DENVER, CO / ACCESS Newswire / September 16, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2025 full year and fourth quarter, after the market close on Tuesday, September 23, 2025. The Company has scheduled a conference call and webcast that same day, Tuesday, September 23, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Tuesday, September 23, 2025, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 447137.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/52803, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until October 7, 2025, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 52803.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
A.Jones--AMWN